{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/glaucoma/background-information/classification/","result":{"pageContext":{"chapter":{"id":"00e7c765-c989-527f-b21f-29ad09409af8","slug":"classification","fullItemName":"Classification","depth":2,"htmlHeader":"<!-- begin field f304572c-83a1-49f3-beab-3987d9b9f0e3 --><h2>How is glaucoma classified?</h2><!-- end field f304572c-83a1-49f3-beab-3987d9b9f0e3 -->","summary":"","htmlStringContent":"<!-- begin item 6fef6562-b718-411b-aeda-8ee2f403d0c2 --><!-- begin field ee5a758b-d89b-42d1-8ad5-99e9662ce3c1 --><ul><li><strong>Glaucoma can be classified according to:</strong><ul><li><strong>Age of onset:</strong> congenital, infantile, juvenile, or adult.</li><li><strong>Cause:</strong> primary (no known cause) or secondary with a known underlying cause.</li><li><strong>Rate of onset: </strong>acute, subacute, or chronic.</li><li><strong>The anterior chamber angle between the iris and cornea</strong><strong>: </strong>being either open or closed.</li></ul></li><li><strong>In open angle situations, </strong>the angle between the iris and the cornea is normal.<ul><li><strong>Primary open angle glaucoma (POAG)</strong> is, by far, the most common type of glaucoma. POAG:<ul><li>Mainly affects people over the age of 40 years.</li><li>Is usually insidious in onset, and follows a chronic course. </li><li>Usually affects both eyes, but one eye may be more affected than the other. </li><li>Is typically associated with raised intraocular pressure (IOP).</li></ul></li><li><strong>Normal tension (pressure) glaucoma </strong>occurs in a significant minority of people with POAG where glaucoma develops with normal IOP. It seems that the optic nerve fibres are more susceptible to damage in some people with intraocular pressures considered to be normal.</li><li><strong>Suspected POAG</strong> is when the appearance of the optic nerve head is suggestive of glaucoma but the visual fields appear normal, or conversely, where a visual field defect exists yet the optic nerve appears healthy.</li><li><strong>Secondary open angle glaucoma</strong> is uncommon and may be due to a number of causes. </li></ul></li><li><strong>In angle closure situations, </strong>the angle between the iris and the cornea is at least partially closed.<ul><li><strong>Primary angle closure glaucoma (PACG)</strong> is the most common type of angle closure glaucoma. Onset may be acute, subacute, or chronic. Terms used prior to PACG developing include:<ul><li>Primary angle closure suspect (PACS) where gonioscopy (examination of the anterior chamber angle) shows some angle closure but the person has normal IOP and no signs of glaucoma.</li><li>Primary angle closure (PAC) where there is more extensive angle closure seen on gonioscopy, often with raised IOP, but with no signs of glaucoma.</li></ul></li><li><strong>Secondary angle closure glaucoma</strong> is uncommon and may be due to a number of causes. </li><li><strong>Symptom development</strong> in primary or secondary angle closure can be classified as:<ul><li><strong>Acute:</strong> this occurs when there is abrupt onset of symptoms (most notably, eye pain) associated with a marked elevation of IOP due to a total closure of the angle. This is a sight-threatening medical emergency that is not self-limiting. </li><li><strong>Subacute (or intermittent):</strong> where there is abrupt onset of symptoms and elevation of IOP due to closure of the angle, but which is self-limiting. It is often recurrent. Glaucoma may develop.</li><li><strong>Chronic:</strong> with gradually elevated IOP resulting from angle closure that is asymptomatic. This is the most common closed angle situation and glaucoma typically develops if not recognised and treated. </li></ul></li></ul></li></ul><p>  [<a class=\"bibliography-reference internal-reference\" href=\"/topics/glaucoma/references/\">Khondkaryan, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/glaucoma/references/\">King, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/glaucoma/references/\">Bowling, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/glaucoma/references/\">NICE, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/glaucoma/references/\">BMJ Best Practice, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/glaucoma/references/\">BMJ Best Practice, 2019</a>]</p><!-- end field ee5a758b-d89b-42d1-8ad5-99e9662ce3c1 --><!-- end item 6fef6562-b718-411b-aeda-8ee2f403d0c2 -->","topic":{"id":"2f2ce020-977b-56c2-bfe0-79af338099b2","topicId":"3f1d1b43-0970-4917-b518-15a04dfd4397","topicName":"Glaucoma","slug":"glaucoma","lastRevised":"Last revised in November 2020","chapters":[{"id":"b70753e1-40bf-5d64-8042-80499a3a3663","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"99932988-c7ac-5201-8a03-324771c52186","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"4665a282-8076-541c-8fdb-d884f514e73a","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"90547efd-385b-5418-95dc-840a239bb4b6","slug":"changes","fullItemName":"Changes"},{"id":"744db240-54ad-5b2b-bde1-fbf5f82dd75c","slug":"update","fullItemName":"Update"}]},{"id":"1b9b2a0b-c1eb-5850-81a4-594deb443996","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"d96d012a-8a50-5197-a3bc-80be922d4ec3","slug":"goals","fullItemName":"Goals"},{"id":"ab168d63-48cb-5e39-af87-b20be5416a2b","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"1371aed7-3648-50af-9b62-765d61209340","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"e5d9b1dc-20e2-5c90-807b-c86643d03e27","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"634d007b-489f-5899-be8c-e79e2c12d416","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"895cf400-6256-5dd3-9e84-20a916980e46","slug":"nice-quality-standards","fullItemName":"NICE Quality standards"}]},{"id":"05123836-33c6-55ab-87b4-82c858ac280b","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"e281b4eb-d1e1-5e3a-ac1e-ba1ce5a60a71","slug":"definition","fullItemName":"Definition"},{"id":"1d1f8e60-4614-5dcc-a66d-9019ca4e6e03","slug":"anatomy-physiology","fullItemName":"Anatomy and physiology"},{"id":"00e7c765-c989-527f-b21f-29ad09409af8","slug":"classification","fullItemName":"Classification"},{"id":"855a9d74-8bb6-54d9-bfc9-5c385ae0f3f4","slug":"causes","fullItemName":"Causes"},{"id":"89456b4f-1b83-5bd6-ba80-018c1171090d","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"37e8081e-c003-5262-a267-bf22817b2d3d","slug":"prevalence","fullItemName":"Prevalence"},{"id":"592dbfb6-31cc-55a6-a38e-b77abbd29565","slug":"prognosis","fullItemName":"Prognosis"},{"id":"f95b1f20-8f4d-5e8f-9e11-426b2a59246a","slug":"complications","fullItemName":"Complications"}]},{"id":"86e2bb04-52a3-5765-8605-aa439e65cf40","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"c3238d06-745f-57aa-b5f9-69dc42896f15","slug":"primary-angle-closure-glaucoma","fullItemName":"Primary angle closure glaucoma"},{"id":"f7c27cd1-50e2-5977-9f46-b1ae6e37f8c6","slug":"ocular-hypertension-primary-open-angle-glaucoma","fullItemName":"Ocular hypertension and primary open angle glaucoma"},{"id":"8f240bf4-5d3c-57ba-a2f7-5e0b82983e5c","slug":"opportunistic-testing-for-glaucoma","fullItemName":"Opportunistic testing for glaucoma"}]},{"id":"c621d247-f521-559a-93ce-c62c3ab5fd2b","fullItemName":"Management","slug":"management","subChapters":[{"id":"1e08cb89-b766-5a2f-9853-4406baa8635c","slug":"acute-angle-closure-angle-closure-glaucoma","fullItemName":"Scenario: Acute angle closure and angle closure glaucoma"},{"id":"803a56e6-2082-5ccc-add9-0d7bd9f32f6a","slug":"primary-open-angle-glaucoma-intraocular-hypertension","fullItemName":"Scenario: Primary open angle glaucoma and intraocular hypertension"}]},{"id":"2d512acb-6e34-566f-8f5f-90eb0d0c8431","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"d784c3ec-391a-5275-a286-56b128e61629","slug":"topical-prostaglandin-analogues-prostamides","fullItemName":"Topical prostaglandin analogues and prostamides"},{"id":"7d644d35-69fa-5a6f-8ceb-fab24019dcee","slug":"topical-beta-blockers","fullItemName":"Topical beta-blockers"},{"id":"7a8c1c4a-8a2d-5555-828d-58b50a740f88","slug":"topical-sympathomimetics","fullItemName":"Topical sympathomimetics"},{"id":"9a1dce0a-a42d-5d80-8ded-a8444facf830","slug":"carbonic-anhydrase-inhibitors","fullItemName":"Carbonic anhydrase inhibitors"},{"id":"efeb705d-eba6-581c-93ad-0916f0aed1c4","slug":"topical-miotics","fullItemName":"Topical miotics"}]},{"id":"657fc5fb-6ac1-5cfe-8fde-6a6eaf21e17b","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"14521c62-39fa-5ea2-9b3b-ba4a79d55565","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"4d0bdf94-c9fe-564d-bd78-4e6e957019c7","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"4dec5995-8a6e-599f-a3ec-4401dda0f2fc","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"fbee715b-cedc-51e6-91f9-00319ab7944f","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"802ad5b9-1cd1-59e9-8b22-2239d0b31c19","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"4211d06e-9a65-51ea-ac4d-d35ca789f223","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"85b73253-be63-5a83-8948-152e3b5a51f7","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"05123836-33c6-55ab-87b4-82c858ac280b","slug":"background-information","fullItemName":"Background information"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}